Danshen (Salvia miltiorrhiza) and prostate

What 2 graded rows on danshen (salvia miltiorrhiza) agree on for prostate, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Danshen (Salvia miltiorrhiza) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Danshen (Salvia miltiorrhiza) page, with its PubMed record.

Supplement

Danshen (Salvia miltiorrhiza) Choose another

2 rows · 166 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade C, is a randomized trial of 136 people (2024) and found an improvement.

The rows run from 30 to 136 people, published from 2024 to 2026: 2 single studies.

2 improved

Grade CLower urinary tract symptoms (IPSS) in men · Improved
RCT · n 136 · 2024 · Men with lower urinary tract symptoms (Korea, multicentre)
400 or 800 mg/day · 12 weeks
Both doses improved total IPSS and several secondary outcomes vs placebo; erectile function (IIEF) improved, especially at 400 mg. PSA and testosterone did not change; no serious adverse events led to discontinuation.
Row on the Danshen (Salvia miltiorrhiza) page · PubMed 39796461 (opens PubMed)
Grade DUrinary symptoms vs saw palmetto · Improved
Pilot RCT · n 30 · 2026 · Men with lower urinary tract symptoms (Korea)
400 mg/day · 12 weeks
Total IPSS fell more with SAGX than saw palmetto (p = 0.031), with better storage symptoms (p = 0.003), quality of life (p = 0.035) and erectile function (p = 0.005).
Row on the Danshen (Salvia miltiorrhiza) page · PubMed 42280395 (opens PubMed)